• Angiotensin III: A Receptor-Aware RAAS Tool

  2026-09-09

  Angiotensin III is more than a downstream RAAS metabolite: its cleavage state, receptor profile, and assay context can change experimental interpretation. This guide connects A1043 product specifications with a 2025 spike–receptor binding study to support better cardiovascular, neuroendocrine, and cross-domain assay design.

• circRNA–FXR/TLR4 Signaling in NiONP Fibrosis

  2026-09-08

  A 2025 Toxics study links hsa_circ_0001944 with FXR/TLR4 signaling, ferroptosis, and nickel oxide nanoparticle-induced collagen deposition in LX-2 hepatic stellate cells. Its combined pharmacological and genetic design suggests a regulatory route from circular RNA loss to FXR suppression, TLR4 elevation, altered ferroptosis, and fibrotic activation, while retaining important limits for translation beyond cell and animal models.

• 4-MUG Assays for Lysosomal Enzyme Research

  2026-09-08

  Use 4-MUG to convert β-glucosidase and β-glucocerebrosidase activity into a sensitive, tunable fluorescence readout. This workflow connects routine enzyme kinetics with GBA1-deficient cell models and functional evaluation of emerging mRNA-LNP strategies for Gaucher disease.

• p53 Inhibition Meets Neuroinflammatory Pain Biology

  2026-09-07

  An evidence-led perspective on using Cyclic Pifithrin-α hydrobromide to test whether p53-dependent stress responses modify the Ca2+-CGRP/SP–Piezo2 circuitry underlying trigeminal mechanical allodynia, while preserving a clear boundary between established evidence and translational hypotheses.

• GSK126 EZH2 Inhibitor: Practical Workflows

  2026-09-07

  Use GSK126 to connect PRC2-dependent gene silencing with measurable chromatin, viability, inflammatory, and autophagy phenotypes. This workflow-oriented guide covers oncology applications, a cautious neuroinflammation bridge, dose design, and troubleshooting for reproducible EZH2 experiments.

• Foretinib (GSK1363089): From Kinase Map to Translation

  2026-09-05

  Foretinib (GSK1363089) offers a translational framework for connecting multikinase biology with more rigorous cancer drug-response measurements. This thought-leadership article examines how Met and VEGFR pathway inhibition, endpoint selection, motility assays, and in vivo modeling can strengthen preclinical decisions.

• GSK 2837808A: LDHA Inhibition Workflow

  2026-09-04

  GSK 2837808A is a potent, selective LDHA inhibitor for separating lactate production from broader glycolytic effects in cancer-cell assays. This workflow emphasizes glucose consumption reduction, assay controls, and cautious translation from hepatocellular carcinoma research to exploratory colorectal cancer metabolism studies.

• Relative and Fractional Viability in Cancer Drug Testing

  2026-09-04

  Hannah R. Schwartz’s dissertation separates relative viability from fractional viability to distinguish proliferative arrest from actual cell killing. Its framework shows that anticancer drugs can affect both processes with different magnitudes and timing, providing a more rigorous basis for assay design and interpretation.

• MnTBAP Chloride: From Redox Signal to Translation

  2026-09-03

  A translational perspective on how MnTBAP Chloride connects mitochondrial superoxide, inflammation, and stress-related phenotypes—and how researchers can design more causally informative preclinical studies.

• NSP15 Inhibitor Screening Identifies Thymopentin

  2026-09-03

  A 2021 structure-based study screened a natural-product library against SARS-CoV-2 NSP15 and identified thymopentin and oleuropein as the strongest computational hits. Molecular-dynamics analyses supported stable protein–ligand complexes, while the absence of biochemical and cellular validation defines the findings as hypothesis-generating rather than evidence of clinical antiviral efficacy.

• Idoxuridine Workflows for Viral DNA Research

  2026-09-02

  Build a more interpretable antiviral workflow around Idoxuridine, from DMSO stock preparation to orthogonal viral DNA and viability readouts. The guide also adapts a rapid, paired-measurement concept from human DRG research while clearly separating methodological inspiration from antiviral evidence.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-09-02

  The reference study identifies CD44 as an essential metabolic dependency in IDH-mutant leukemia, linking altered glucose handling to NADPH supply and sustained R-2HG production. Its isogenic CRISPR-based design supports a combination strategy in which mutant-IDH inhibition is paired with CD44 blockade to improve leukemia-cell elimination.

• GSK J4 HCl: JMJD3 Inhibitor Guide

  2026-09-01

  GSK J4 HCl is a cell-permeable JMJD3 inhibitor prodrug used to study H3K27 demethylation, inflammatory signaling, and cancer biology. Its intracellular conversion to GSK J1 is central to interpreting enzyme, macrophage, and tumor-model data.

• GSK126 EZH2 Inhibitor for Reliable Cell Assays

  2026-09-01

  A scenario-based guide to using GSK126 EZH2 inhibitor (SKU A3446) in cell viability, proliferation, and cytotoxicity workflows. It connects EZH2/PRC2 biology with practical dosing, compound handling, controls, data interpretation, and evidence-based vendor selection.

• High Glucose, BVO Vasculogenesis, and hucMSC Rescue

  2026-08-31

  The 2024 iScience study by Yao, Shan, and Li uses blood vessel organoids to distinguish glucose injury during vasculogenesis from later angiogenic remodeling. Its findings indicate that vascular-lineage induction is especially glucose-sensitive and that human umbilical cord-derived mesenchymal stem cells can partially restore endothelial differentiation and function through MAPK pathway downregulation.

7794 records 1/520 page Next 12345 下5页 Last page